MARC Record from harvard_bibliographic_metadata

LEADER: 04402cam a22004094a 4500
001 011323921-1
005 20071219120548.0
008 061213s2008 fluaf b 001 0 eng
010 $a 2006101712
015 $aGBA771974$2bnb
016 7 $a101295385$2DNLM
016 7 $a013763130$2Uk
020 $a9780849387968 (alk. paper)
020 $a0849387965 (alk. paper)
035 0 $aocm77011618
040 $aDNLM/DLC$cDLC$dBAKER$dBTCTA$dNLM$dC#P$dYDXCP$dUKM$dDLC
042 $apcc
050 00 $aRM666.A564$bA567 2008
060 00 $a2007 I-960
060 10 $aQU 57$bA6324 2008
082 00 $a615/.31$222
245 00 $aAntisense drug technology :$bprinciples, strategies, and applications /$cedited by Stanley T. Crooke.
250 $a2nd ed.
260 $aBoca Raton :$bCRC Press,$cc2008.
300 $axvii, 825 p., [12] p. of plates :$bill. (some col.) ;$c27 cm.
504 $aIncludes bibliographical references and index.
505 0 $aMechanisms of antisense drug action, an introduction / Stanley T. Crooke ... [et al.] -- The RNase H mechanism / Walt Lima, Hongjiang Wu, and Stanley T. Crooke -- Small RNA silencing pathways / Alla Sigova and Phillip D. Zamore -- Splice switching oligonucleotides as potential therapeutics / Peter Sazani, Maria A. Graziewicz, and Ryszard Kole -- Basic principles of antisense drug discovery / Susan M. Freier and Andrew T. Watt -- The medicinal chemistry of oligonucleotides / Eric E. Swayze and Balkrishen Bhat -- Basic principles of the pharmacokinetics of antisense oligonucleotide drugs / Arthur A. Levin, Rosie Z. Yu, and Richard S. Geary.
505 8 $aRoutes and formulations for delivery of antisense oligonucleotides / Gregory E. Hardee, Lloyd G. Tillman, and Richard S. Geary -- Liposomal formulations for nucleic acid delivery / Ian MacLachlan -- Pharmacological properties of 2'-O-methoxyethyl-modified oligonucleotides / C. Frank Bennett -- Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man / Richard S. Geary ... [et al.] -- Toxicologic properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man / Scott P. Henry ... [et al.].
505 8 $aAn overview of the clinical safety experience of first- and second-generation antisense oligonucleotides / T. Jesse Kwoh -- Manufacturing and analytical processes for 2'-O-(2-methoxyethyl)-modified oligonucleotides / Daniel C. Capaldi and Anthony N. Scozzari -- Utilizing chemistry to harness RNA interference pathways for therapeutics : chemically modified siRNAs and antagomirs / Muthiah Manoharan and Kallanthottathil G. Rajeev -- Discovery and development of RNAi therapeutics / Antonin R. deFougerolles and John M. Maraganore -- Optimization of second-generation antisense drugs: going beyond generation 2.0 / Brett P. Monia ... [et al.].
505 8 $aModulating gene function with peptide nucleic acids (PNA) / Peter E. Nielsen -- Locked nucleic acid / Troels Koch and Henrik Ørum -- Morpholinos / Patrick L. Iversen -- Potential therapeutic applications of antisense oligonucleotides in ophthalmology / Lisa R. Grillone and Scott P. Henry -- Cardiovascular therapeutic applications / Rosanne M. Crooke, Brenda Baker, and Mark Wedel -- Developing antisense drugs for metabolic diseases: a novel therapeutic approach / Sanjay Bhanot -- Inflammatory diseases / Susan A. Gregory and James G. Karras -- Antisense oligonucleotides for the treatment of cancer / Boris A. Hadaschik and Martin E. Gleave.
505 8 $aTargeting neurological disorders with antisense oligonucleotides / Richard A. Smith and Timothy M. Miller -- Mechanisms and therapeutic applications of immune modulatory oligodeoxynucleotide and oligoribonucleotide ligands for toll-like receptors / Jörg Vollmer and Arthur M. Krieg -- Aptamer opportunities and challenges / Charles Wilson.
520 $aThis second edition continues to offer answers to challenging questions while looking ahead to the future of antisense drugs, covering the fundamentals of oligonucleotide-based therapeutics and hybridization-based drugs as well as therapeutic applications for cardiovascular purposes, metabolic diseases, and cancer.
650 0 $aAntisense nucleic acids$xTherapeutic use.
650 12 $aOligonucleotides, Antisense$xtherapeutic use.
700 1 $aCrooke, Stanley T.
988 $a20071204
906 $0OCLC